Sumatriptan intranasal - OptiNose

Drug Profile

Sumatriptan intranasal - OptiNose

Alternative Names: AVP-825; ONZETRA Xsail; OptiNose sumatriptan

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OptiNose AS
  • Developer Avanir Pharmaceuticals; OptiNose
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 02 Nov 2017 Phase-III clinical trials in Migraine (In adolescents) in USA (Intranasal) (NCT03338920)
  • 11 May 2017 Discontinued - Phase-II for Migraine in Czech Republic (Intranasal)
  • 21 Apr 2017 Interim efficacy and safety data from the phase III COMPASS trial in Migraine presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top